This contemporary, international, evidence-informed guidance aims to achieve the greatest
good for the greatest number of people with familial hypercholesterolaemia (FH) across …

Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth
that markedly elevates plasma low-density lipoprotein (LDL) cholesterol and causes …

Familial hypercholesterolemia (FH) is a dominantly inherited disorder present from birth that
markedly elevates plasma low-density lipoprotein cholesterol and causes premature …

Familial hypercholesterolemia (FH) is the most common genetic disorder causing premature
cardiovascular disease and death. Heterozygous FH conservatively affects approximately 1 …

Importance Familial hypercholesterolemia (FH) is an underdiagnosed and undertreated
genetic disorder that leads to premature morbidity and mortality due to atherosclerotic …

This 2023 statement updates clinical guidance for homozygous familial
hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic …

Objective To summarize the pathophysiology, epidemiology, screening, diagnosis, and
treatment of familial hypercholesterolemia (FH). Quality of evidence A PubMed search was …

Familial Hypercholesterolaemia (FH) is the commonest autosomal co-dominantly inherited
condition affecting man. It is caused by mutation in one of three genes, encoding the low …

Familial hypercholesterolaemia (FH) is a dominant and highly penetrant monogenic
disorder present from birth that markedly elevates plasma low-density lipoprotein (LDL) …

Familial hypercholesterolemia (FH) is the most common monogenic disorder causing
premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide …